ENZO BIOCHEM (NYSE: ENZ), revealed offering IAN B. WALTERS, chair in its boardroom

Related Topics

Facebook
Twitter
LinkedIn
WhatsApp

Enzo Biochem, Inc. (NYSE: ENZ), a prominent bioscience and diagnostics firm, officially revealed the immediate addition of Ian B. Walters, MD, to the Board of Directors of the Company.

Dr. Walters is an accomplished entrepreneur and drug manufacturer with leadership in creating more than 30 products in different clinical fields comprising diverse innovations, resulting in five new approvals of oncology drugs. His former roles include Bristol-Myers Squibb’s Executive Director of Global Oncology Clinical Science and Market Growth, and Millennium Pharmaceuticals Medical Director. Dr. Walters is currently the CEO and Owner of Portage Biotech, a publicly listed biopharmaceutical clinical-stage business that is building an advanced immuno-oncology asset portfolio. He is also the founder of seven portfolio companies owned by Portage.

Dr. Walters holds an MBA from the University of Pennsylvania, Wharton School. He obtained his MD from the Albert Einstein College of Medicine and finished his doctoral studies at Rockefeller University in experimental medicine. The main author or contributor to nearly 60 journal articles has been Dr. Walters.

According to Dr. Elazar Rabbani, Ph.D., Chairman, and Chief Executive Officer of Enzo, Dr. Walters has over two decades of diverse expertise in drug production and corporate management, including both founding and executive roles at many life sciences firms. His deep experience includes professional growth, regulatory affairs, and strategic strategy as a specialist, scientist, and entrepreneur. Dr. Walters will play an instrumental role in finding innovative directions in which Enzo’s offerings will successfully help companion diagnostics, early drug exploration, and liquid biopsy techniques at a time when we have reported promising development and continuing momentum going into 2021.

Via its swift reaction to the COVID-19 pandemic and ongoing deployment of cost-effective, adaptive technology to solve key problems in the clinical diagnostics industry, Enzo continues to prove its position as a revolutionary pioneer, said Dr. Walters. I am excited to work closely with the other senior executives and the management team of Enzo to ensure its continued sustainability and to target new growth opportunities.

Leave a Comment

Your email address will not be published.

Top ev stock

Five Top EV Stocks to Buy Right Now

The push towards electrification and decarbonization has never been more apparent. With governments and international institutions on the same page as climate change activists, the

Latest Posts